問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間：2023-09-19

蔡慧珍Tsai, Hui-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡慧珍

List

52Cases

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Terminated10Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-01-06 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2019-03-01 - 2022-12-12

Phase II

A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    M7824

Participate Sites
3Sites

Terminated3Sites

2016-07-01 - 2019-12-31

Phase I

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C (M7824) in subjects with metastatic or locally advanced solid tumors with expansion to selected indications in Asia

  • Condition/Disease

    metastatic or locally advanced solid tumors

  • Test Drug

    MSB0011359C (M7824)

Participate Sites
5Sites

Terminated5Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-12-01 - 2023-12-31

Phase III

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements-FOENIX-CCA3

  • Condition/Disease

    Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  • Test Drug

    Futibatinib（TAS-120）

Participate Sites
6Sites

Recruiting6Sites

2013-07-01 - 2015-01-31

Phase II

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

  • Condition/Disease

    Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

  • Test Drug

    MM-111

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2007-11-01 - 2010-04-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-02-01 - 2009-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB